Response to therapy as determined by minimal residual disease (MRD) is currently used for stratification in treatment protocols for pediatric acute lymphoblastic leukemia (ALL). However, the large MRD-based medium risk group (MRD-M; 50-60% of the patients) harbors many relapses. We analyzed MRD in 131 uniformly treated precursor-B-ALL patients and evaluated whether combined MRD and IKZF1 (Ikaros zinc finger-1) alteration status can improve risk stratification. We confirmed the strong prognostic significance of MRD classification, which was independent of IKZF1 alterations. Notably, 8 of the 11 relapsed cases in the large MRD-M group (n ¼ 81; 62%) harbored an IKZF1 alteration. Integration of both MRD and IKZF1 status resulted in a favorable outcome group (n ¼ 104; 5 relapses) and a poor outcome group (n ¼ 27; 19 relapses), and showed a stronger prognostic value than each of the established risk factors alone (hazard ratio (95%CI): 24.98 (8.29-75.31)). Importantly, whereas MRD and IKZF1 status alone identified only 46 and 54% of the relapses, respectively, their integrated use allowed prediction of 79% of all the relapses with 93% specificity. Because of the unprecedented sensitivity in upfront relapse prediction, the combined parameters have high potential for future risk stratification, particularly for patients originally classified as non-high risk, such as the large group of MRD-M patients.
Introduction
Treatment results of children with acute lymphoblastic leukemia (ALL) have improved dramatically over the last decades, which is at least in part because of improved risk stratification. Children with a high risk of relapse are eligible for more intensive therapy regimens than children with a lower relapse risk. Therefore, early recognition of patients at risk of relapse is of utmost importance in the treatment of children with ALL.
The dexamethasone-based DCOG ALL9 study turned out to be very successful with a 5-year event-free survival rate of 81% and an overall survival rate of 85%. 1 In this study, patients were stratified into non-high-risk (NHR) and high-risk (HR) treatment arms based on white blood cell count at diagnosis, mediastinal mass, CNS and testicular involvement, and the presence of BCR-ABL1 or MLL gene rearrangements. The NHR group encompassed two-third of the patients and showed event-free survival rates above 82%. 1 Nevertheless, this treatment arm also contained 470% of all the relapses, suggesting that considerable improvements can be made through the identification and implementation of new risk factors for relapse.
The analysis of minimal residual disease (MRD) at different time points during treatment has proven to serve as an accurate prognostic parameter for disease outcome. [2] [3] [4] [5] [6] [7] [8] Furthermore, genomic analyses in pediatric ALL recently revealed that deletions of the Ikaros zinc finger-1 (IKZF1) gene are associated with a poor prognosis. 9, 10 A major challenge in the current risk stratification models of children with precursor-B-ALL lies in the fact that the majority of relapses still occur in the treatment groups where the relapse risk is relatively low. MRD classification, for example, clearly identifies patients at low or at high risk for relapse, but it also results in a large intermediate group, which still contains B50% of all the relapse cases.
In the present study, using a well-defined cohort of patients enrolled in the recently published DCOG ALL-9 protocol, 1 we show that integration of MRD classification and IKZF1 alteration status greatly improves the upfront identification of patients with a high chance of relapse.
Patients and methods

Patient characteristics
We collected patients diagnosed with ALL between January 1997 and December 1999. Out of a total of 332 patients diagnosed within this period, 131 patients are the subject of this study, based on (1) enrollment in the DCOG ALL9 protocol; (2) complete remission status after induction therapy (that is, o5% blasts in bone marrow and absence of blasts in peripheral blood, CSF and other organs); (3) precursor-B-ALL immunophenotype; (4) prospectively determined MRD data available; and (5) known IKZF1 deletion status (Supplementary Table S1 ). Our cohort of 131 patients showed clinical characteristics that did not differ significantly from the entire group of precursor-B-ALL patients included in the ALL9 protocol (Supplementary Table S2 ). The DCOG ALL9 treatment protocol stratifies patients into HR and NHR treatment groups based on white blood cell count at diagnosis, mediastinal mass, central nervous system or testicular involvement at diagnosis, and the presence of BCR-ABL1 or MLL gene rearrangements. 1 In our cohort, 102 patients were enrolled in the NHR treatment arm and 29 in the HR treatment arm. A total of 24 patients (18%) relapsed of which 18 died (75%) (Supplementary Table S3 ). Median follow-up time was 10 years (1-12 years) and all surviving patients have been followed for at least 9 years.
MRD classification
Immunoglobulin and T cell-receptor gene rearrangements were detected in the diagnostic specimens as described previously. [11] [12] [13] [14] [15] Based on the junctional region of the identified rearrangements, patient-specific primers were designed and tested for sensitivity and specificity in a real-time quantitative PCR assay. 12, 14, [16] [17] [18] [19] MRD levels were determined in bone marrow samples obtained at day 42 (end of induction therapy; time point 1) and day 84 (time point 2) after start of treatment. If analysis of the same bone marrow sample with two or more different PCR targets resulted in different tumor-load estimations, the highest MRD level was assumed to be most accurate and used for all subsequent data analyses. 2, 4 Both Dutch MRD-PCR laboratories (Erasmus MC and Sanquin) participated in the Quality Assurance program of the European Study Group on MRD detection in ALL (now called EuroMRD). 7, 8 Data were interpreted according to recently published guidelines. 8 For each patient, we aimed for at least one marker with a quantitative range of 10 À4 and a second marker with a quantitative range of at least 5 Â 10
À4
, and a sensitivity of 10 À5 . Based on the MRD data at days 42 and 84, patients were divided into three groups using the classification system found to be most informative in our previous study.
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The MRD-Low (MRD-L) group contained patients who were MRD negative at both the time points. Patients in the MRDMedium (MRD-M) group had detectable MRD at the time point 1 and/or 2, but an MRD level p5x10 À4 at the time point 2. Finally, the MRD-High (MRD-H) group consisted of patients with strongly positive MRD levels (45 Â 10 À4 ) at the time point 2. Patients without two sensitive targets (as defined above) were included if (i) the MRD level detected was sufficiently high to be quantified despite a lower quantitative range or if (ii) both targets had a quantitative range of 5 Â 10 À4 and at least one of the follow-up samples was positive (o5 Â 10 À4 ).
Data analysis
We employed the w 2 test, univariate and multivariate Cox regression analyses, Kaplan and Meier survival curves (including 108 months of follow-up) and log-rank testing using the SPSS statistical package (release 16.0.2, April 2008; SPSS inc., Chicago, IL, USA). 10 Multivariate analysis was performed with stepwise removal of non-significant factors, and relapse-free survival (RFS) was defined by the time from diagnosis to the first relapse.
Results
MRD analysis
Based on MRD levels on days 42 and 84, patients were divided into three groups; 34 patients were classified as MRD-L (26%), 81 patients as MRD-M (62%) and 16 patients as MRD-H (12%).
MRD classification strongly associated with relapse occurrence (Po0.001; Table 1 ), and in both MRD-L and MRD-M groups, the 9-year RFS rates were high (94 and 86%, respectively), compared with only 31% in the MRD-H group (Po0.001; Figure 1 ). Furthermore, when both treatment arms were analyzed separately, MRD classification showed a strong association with the occurrence of relapse (NHR Po0.001 and HR P ¼ 0.005; Supplementary Tables S4 and S5) and RFS rates were discriminative between the MRD-L/MRD-M and the MRD-H groups (Po0.001; Supplementary Figure S1 ). These data show that in both the HR and NHR treatment arms of ALL9, high levels of MRD serve as strong indicators of relapse. Nevertheless, almost half of all the relapses (46%) occurred 
IKZF1 alteration status divides MRD-M class
In addition to the recently described IKZF1 deletions, 10 we determined the IKZF1 sequence mutation status in this cohort. Mutations were not frequent (n ¼ 2, c.104_105ins14 and c.422-34_446del58ins8; Table 1 ) and added only slightly to the prognostic value of IKZF1 status. Patients harboring an IKZF1 alteration (either deletion or mutation) showed a RFS of only 35% (Supplementary Figure S1) , and again about half of all the relapses (47%) could not be predicted based on IKZF1 alteration status alone.
Strikingly, in the large MRD-M group (n ¼ 81; 62% of the patients), containing 46% of the relapsed patients, IKZF1 alteration status distinguished patients with good outcome from patients with poor outcome. The 9-year RFS for IKZF1-alterated patients in this group was 27% compared with 96% for patients that were wild type for IKZF1 (Po0.001; Figure 2b ). Moreover, IKZF1 alteration status identified 8 out of the 11 relapsed MRD-M-classified patients (72%). In the MRD-H and MRD-L groups, the IKZF1 status did not have a significant impact on RFS (Figures 2a and c; Supplementary Figure S2 ).
Integration shows unprecedented sensitivity
To further evaluate the impact of these results, we integrated both MRD and IKZF1 status. In the favorable outcome group, we included all patients classified as MRD-L and MRD-M patients with IKZF1 wild type (n ¼ 104), whereas the poor outcome group consisted of all the MRD-H and MRD-M patients with IKZF1 alterations (n ¼ 27). The favorable outcome group had superior 9-year RFS rates (95%, 5 relapses) compared with the poor outcome group (30%, 19 relapses; Figure 3 , Supplementary Figure S3) . The fact that similar results were obtained for both the HR and NHR treatment arms (Figures 3b and c) suggests that this subdivision is not influenced by treatment intensity or standard risk markers used for risk stratification at diagnosis in this treatment protocol (for example, BCR-ABL1 translocations, white blood cell count at diagnosis). This was confirmed by multivariate analysis, in which the integrated parameter showed to have stronger prognostic value than each of the established risk factors alone (hazard ratio (95% CI): 24.98 (8.29-75.31); Supplementary Table S6) .
Importantly, whereas MRD and IKZF1 status alone identified only 46 and 54% of the relapses, respectively (Supplementary  Table S7 ), their integrated use allowed prediction of 79% of all the relapses with 93% specificity (Table 2) . Out of the 24 relapse cases, 17 (70%) were originally not classified as being at high risk for relapse based on DCOG-ALL9 stratification criteria (NHR treatment arm). In this group, the combined IKZF1/MRDbased stratification correctly identifies 14 out of the 17 relapse patients (82%).
Discussion
Early recognition of patients with high risk of relapse is of utmost importance in the treatment of children with ALL. In this study, we analyzed the combined prognostic value of two risk factors, MRD classification and IKZF1 alteration status, in a representative cohort of 131 pediatric precursor B-cell ALL patients enrolled in the Dutch DCOG-ALL9 study. We confirm that MRD classification is a strong and independent prognostic factor for RFS. Most importantly, in the large MRD-M group, which consists of patients with intermediate RFS rates, we show that IKZF1 alteration status specifically and sensitively identifies patients who develop a relapse. As a consequence, the integrated use of MRD classification and IKZF1 alteration status shows an unprecedented relapse prediction rate of nearly 80% of the relapses. Notably, the majority of these relapse cases (70%) were considered 'NHR' based on the original risk-group classification.
The level of MRD at different time points during treatment of childhood ALL has proven to be a very accurate prognostic parameter for treatment outcome. [2] [3] [4] [5] [6] 20 For the MRD-based classification, we used the criteria established in a previous DCOG ALL8 study (similar to the I-BFM-SG MRD study 91). This classification also appears to distinguish high-, intermediate-and low-risk patients treated according to the significantly different DCOG-ALL9 protocol (relapse rates 69, 14 and 6%, respectively). Whether alternative cutoff points and risk-group definitions may be more appropriate is currently under investigation (Van der Velden et al., manuscript in preparation). 
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The selective use of patients enrolled in the DCOG-ALL9 protocol allowed us to study the impact of MRD classification and IKZF1 alteration status independent of differences in treatment. Within DCOG-ALL9, MRD analysis was performed as an add-on study and was not used for treatment stratification. In total, 17% of the patients were excluded from the study because of the lack of (sensitive) MRD-PCR targets, which is comparable with previous reports. 3, 4 However, as the clinical significance of MRD was not yet well established at the start of the DCOG ALL9 protocol (early 1997), some clinical centers failed to collect material for MRD analysis from the start onwards, resulting in a relatively high number of patients (n ¼ 70) that was excluded because of lack of sufficient diagnosis or follow-up material. Nevertheless, our cohort was sufficiently large to significantly demonstrate the strong added value of IKZF1 alteration status in the MRD-M group, both in the entire cohort as well as in the relatively large subgroup of uniformly treated NHR-classified patients.
The size of our cohort does not allow us to draw firm conclusions on the impact of IKZF1 alterations in patients classified as MRD-L and MRD-H, respectively. The fact that three MRD-L-classified patients with IKZF1 deletions did not develop a relapse may suggest that the absence of detectable levels of MRD has stronger prognostic significance than the presence of IKZF1 alterations. Alternatively, IKZF1 mutant cases may be considered at increased risk for relapse irrespective of MRD status, as the presence of IKZF1 alterations in the MRD-H group shows a tendency to worse RFS. Obviously, future studies on much larger cohorts are needed to further elucidate the mutual effect of these two prognostic factors on outcome.
We anticipate that the combined use of MRD classification and IKZF1 alteration status for risk stratification in future treatment protocols will have several major advances. First, these criteria identify a relatively small group of patients with poor outcome encompassing the vast majority of all relapses and including many patients (82%) currently not recognized as at high risk using the established risk factors. These patients may benefit from alternative, intensified or novel treatment strategies. Second, the remaining large group of patients with favorable prognosis has an extremely low relapse rate (o5% compared with B12% in the NHR group of ALL9). Future studies may reveal whether these patients benefit from treatment reduction. In conclusion, the combined use of MRD classification and IKZF1 alteration status has a high potential for future risk stratification. The poor outcome group contains all patients with MRD-H classification and MRD-M patients with altered IKZF1.
